Hemostemix (CVE:HEM) Stock Price Down 19.4% – Time to Sell?

Hemostemix Inc. (CVE:HEM) was down 19.4% during mid-day trading on Wednesday . The company traded as low as C$0.14 and last traded at C$0.15. Approximately 519,694 shares traded hands during trading, a decline of 1% from the average daily volume of 526,987 shares. The stock had previously closed at C$0.18.

Hemostemix Trading Down 19.4 %

The stock has a market capitalization of C$21.13 million, a P/E ratio of -4.23 and a beta of 0.20. The company has a quick ratio of 0.48, a current ratio of 0.04 and a debt-to-equity ratio of -55.07. The stock’s 50 day moving average price is C$0.19 and its 200-day moving average price is C$0.12.

About Hemostemix

Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.